La Jolla Pharmaceutical (NASDAQ:LJPC) has been given a consensus rating of “Hold” by the nine analysts that are currently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $49.33.

Several analysts have recently weighed in on LJPC shares. Jefferies Group reiterated a “buy” rating and issued a $40.00 price objective on shares of La Jolla Pharmaceutical in a research note on Tuesday, October 3rd. Zacks Investment Research upgraded shares of La Jolla Pharmaceutical from a “hold” rating to a “buy” rating and set a $39.00 price objective for the company in a research note on Wednesday, November 1st. Cowen reiterated a “buy” rating and issued a $55.00 price objective on shares of La Jolla Pharmaceutical in a research note on Friday, October 27th. J P Morgan Chase & Co started coverage on shares of La Jolla Pharmaceutical in a research note on Wednesday, August 30th. They issued an “overweight” rating and a $36.00 price objective for the company. Finally, ValuEngine lowered shares of La Jolla Pharmaceutical from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st.

Large investors have recently added to or reduced their stakes in the company. Legal & General Group Plc grew its position in La Jolla Pharmaceutical by 11.6% in the 2nd quarter. Legal & General Group Plc now owns 4,456 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 462 shares during the period. Jane Street Group LLC acquired a new stake in La Jolla Pharmaceutical in the 3rd quarter valued at $200,000. Trexquant Investment LP acquired a new stake in La Jolla Pharmaceutical in the 3rd quarter valued at $217,000. Voya Investment Management LLC acquired a new stake in La Jolla Pharmaceutical in the 2nd quarter valued at $243,000. Finally, Nationwide Fund Advisors grew its position in La Jolla Pharmaceutical by 20.4% in the 2nd quarter. Nationwide Fund Advisors now owns 9,952 shares of the biopharmaceutical company’s stock valued at $296,000 after purchasing an additional 1,688 shares during the period.

La Jolla Pharmaceutical (NASDAQ:LJPC) traded up $0.85 during trading on Monday, reaching $28.10. 1,512,975 shares of the company’s stock traded hands, compared to its average volume of 454,313. La Jolla Pharmaceutical has a 52-week low of $16.41 and a 52-week high of $39.28.

La Jolla Pharmaceutical (NASDAQ:LJPC) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported ($1.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.24) by $0.05. sell-side analysts forecast that La Jolla Pharmaceutical will post -4.93 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This story was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/12/11/la-jolla-pharmaceutical-ljpc-receives-consensus-recommendation-of-hold-from-analysts.html.

La Jolla Pharmaceutical Company Profile

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).

Analyst Recommendations for La Jolla Pharmaceutical (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.